NewcelX FY26 H1 net loss attributable to common shareholders narrows 50% to USD 5.63 million

NewcelX posted a net loss attributable to common shareholders of USD 5.63 million for the six months ended June 30, 2026. Operating loss widened 107.86% to USD 2.83 million, while total loss narrowed 74.23% to USD 2.9 million. Research and development costs more than doubled to USD 1.17 million, and general and administrative expenses climbed 142.77% to USD 1.66 million. Cash and cash equivalents fell to USD 710,400 at June 30, 2026 from USD 2.2 million at Dec. 31, 2025. Management flagged substantial doubt about going concern, citing uncertainty over fundraising and timing of equity line of credit use. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-101419), on September 18, 2026, and is s